Korsana Biosciences (KRSA) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 96.2% versus a loss of 51.1%. Over five years, RARE leads with a -80.7% price change compared with -91.0% for KRSA. Korsana Biosciences is the larger company by market cap ($1.54 billion vs $1.53 billion), about 1.0 times the size, while Ultragenyx Pharmaceutical is growing revenue faster (+20.2% vs +3.7%).
Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -170.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | RARE |
|---|---|---|
| Share price | $33.92 | $15.48 |
| Market cap | $1.54B | $1.53B |
| 1-day change | +1.22% | +1.24% |
| YTD return | +281.55% | -32.70% |
| 1-year return | +96.18% | -51.11% |
| 5-year return | -90.99% | -80.65% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-7.07 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | $673.00M |
| Revenue growth (YoY) | +3.70% | +20.18% |
| Net income (latest FY) | $-3.53M | $-575.00M |
| Operating margin | -239.78% | -79.49% |
| Net margin | -170.11% | -85.44% |
| 52-week high | $59.36 | $39.89 |
| 52-week low | $7.19 | $12.73 |
| Distance from 52-week high | -42.86% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +29.72% | +73.06% |
| Average volume | 32.51K | 3.90M |
| Shares outstanding | 45.54M | 98.59M |
| Employees | 19 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed RARE by 147.3 percentage points over the past year.
- Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
- Ultragenyx Pharmaceutical grew revenue faster in its latest fiscal year (+20.18% vs +3.70%).
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
KRSA vs RARE FAQ
Which is bigger, Korsana Biosciences or Ultragenyx Pharmaceutical?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.54B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, KRSA or RARE?
KRSA returned +96.18% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.